Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
GHK-Cu (Oral) vs Vesugen
An educational, source-based comparison of GHK-Cu (Oral) and Vesugen — how each peptide works, what it's researched for, and what to know before going deeper.
An oral formulation of the GHK-Cu tripeptide designed for systemic absorption. Research suggests the same copper-complex gene-modulating activity as topical forms, potentially supporting systemic tissue repair, immune modulation, and antioxidant capacity.
- Systemic tissue repair and regeneration
- Immune modulation and inflammation
- Lung and gut tissue health
- Age-related gene expression restoration
- • Oral bioavailability is lower than injectable; optimal dosing unclear.
- • Not FDA-approved for therapeutic use.
A synthetic tripeptide (Lys-Glu-Asp) in the Khavinson bioregulator family. Research indicates modulation of endothelial cell function and vascular wall gene expression, supporting vascular tone and microcirculation.
- Vascular endothelial function
- Microcirculation in aging
- Peripheral vascular disorders
- • Russian-origin research; independent replication limited.
- • Not FDA-approved.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| GHK-Cu (Oral) | Oral GHK-Cu absorption and systemic effects | BioMed Research International | 2021 | Detected in plasma after oral administration with modulated inflammatory biomarkers. |
| Vesugen | Vesugen and vascular endothelial gene expression | Bulletin of Experimental Biology and Medicine | 2014 | Enhanced endothelial nitric oxide synthase expression in vascular tissue models. |
Side-effect & safety grid
- Oral bioavailability is lower than injectable; optimal dosing unclear.
- Not FDA-approved for therapeutic use.
- Russian-origin research; independent replication limited.
- Not FDA-approved.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
GHK-Cu (Oral) vs Vesugen — Key differences
- Class: GHK-Cu (Oral) is classified as Systemic · Regeneration, while Vesugen is Vascular · Bioregulator.
- Primary research focus: GHK-Cu (Oral) — systemic tissue repair and regeneration; Vesugen — vascular endothelial function.
- Tag: Systemic · Anti-aging vs Vascular · Bioregulator.